AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Group)

• 21 Dividends to shareholders
• 22 Acquisitions of business operations
• 23 Post-retirement benefits
• 24 Employee costs and share option plans for employees
• 25 Commitments and contingent liabilities
• 26 Leases
• 27 Statutory and other information

27 Statutory and other information

	2008 $m	2007 $m	2006 $m
Fees payable to KPMG Audit Plc and its associates: Group audit fee	3.2	3.6	3.1
Fees payable to KPMG Audit Plc and its associates for other services: The audit of subsidiaries pursuant to legislation	7.1	6.1	5.4
Other services pursuant to legislation	3.3	3.6	4.1
Taxation	0.9	1.1	1.2
All other services	1.7	0.7	1.0
Fees payable to KPMG Audit Plc in respect of the Group’s pension schemes: The audit of subsidiaries’ pension schemes	0.6	0.6	0.5
	16.8	15.7	15.3

Other services pursuant to legislation includes fees of $2.5m (2007: $2.7m; 2006: $3.2m) in respect of section 404 of the Sarbanes-Oxley Act.

Taxation services consist of tax compliance services and tax advice.

Related party transactions

The Group had no material related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements.

Key management personnel compensation

Key management personnel are defined for the purpose of disclosure under IAS 24 ‘Related Party Disclosures’ as the Board of Directors, the Senior Executive Team and the Company Secretary.

	2008 $’000	2007 $’000	2006 $’000
Short-term employee benefits	21,973	31,525	21,321
Post-employment benefits	2,290	2,072	3,191
Share-based payments	13,210	11,515	8,417
	37,473	45,112	32,929

Short-term employee benefits in 2007 include one-off employee costs of $11m in relation to the acquisition of MedImmune.

Total remuneration is included within employee costs (Note 24).

Subsequent events

There were no material subsequent events.

Back to the top